



Journal of **COMMERCIAL BIOTECHNOLOGY**

OCTOBER 2012

VOLUME 18 | NUMBER 4

ISSN: 1462-8732 / eISSN 1478-565X

WWW.COMMERCIALBIOTECHNOLOGY.COM

Journal of COMMERCIAL BIOTECHNOLOGY

VOLUME 18

NUMBER 4

OCTOBER 2012

Contents

The birth of a discipline: Bioentrepreneurship <i>Arlen Meyers</i>	3
Not fully harmonized: Differences in biotechnology patenting between Europe and the United States <i>Brian R. Dorn, Zoë Birtle</i>	5
Biotechnology in Brazil: An industry overview <i>Ezequiel Zylberberg, Claudia Zylberberg, Asli Ceylan Oner</i>	9
CROs in Modern-day China <i>Steven S. Ma</i>	19
Analyzing the broadening scope of patentability in the advancing field of biotechnology <i>Jessica Downing</i>	27
Lessons on emerging markets and global health <i>Victoria Y. Fan, Bryan A. Liang</i>	34
The Partnership for Safe Medicines—India: Lessons for Partnerships in Emerging Markets <i>Bejon Misra</i>	36
Emerging markets and differential pricing policies: A question of global health? <i>James N. Class</i>	40
Global health diplomacy and management mechanisms of US-China public health collaborations in China: Lessons for emerging markets <i>Matthew Brown, Tim K. Mackey, Bryan A. Liang</i>	44
Blood supply and safety in the developing world: Considerations for emerging markets <i>William Riley, Jeffry McCullough</i>	51
Globalization, evolution and emergence of direct-to-consumer advertising: Are emerging markets the next pharmaceutical marketing frontier? <i>Tim K. Mackey, Bryan A. Liang</i>	59
Tipping point: Biosimilars, emerging markets, and public-private engagement to promote global health <i>Bryan A. Liang, Timothy Mackey</i>	66

Continued ...

While every effort is made to see that no inaccurate data, opinion or statement appears in this journal, the Publishers and the Editors wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor(s) or advertiser(s) concerned. Accordingly, the Publishers, the Editors and their respective employees, officers and agents accept no liability whatsoever for the consequences of such inaccurate or misleading data, opinion or statement.

Biomarketing strategy and tactics 101: Part III of III
Dimitris Dogramatzis

76

The University of California, Davis, collaborative model for biotechnology education and training
Judith A. Kjelstrom, Karen McDonald, Andrew Hargadon, Wilton Agatstein

88